Santhera Presents Data from 2-Year Open-Label Intervention Study with Catena® in Duchenne Muscular Dystrophy at the MYOLOGY 2011 Conference | Reuters

Santhera Presents Data from 2-Year Open-Label Intervention Study with Catena® in Duchenne Muscular Dystrophy at the MYOLOGY 2011 Conference | Reuters: "Santhera Pharmaceuticals (SIX: SANN) announced today that it will present first analyses of the 2-year open-label study (DELPHI-E) evaluating Catena® for the treatment of Duchenne Muscular Dystrophy. The findings indicate that Catena® can slow the decline in respiratory function associated with patients as they age. Data will be presented on May 9, 2011 in Lille, France at the 4th International Congress of Myology [1].
"